FDA requests input on development of user fee program for
FDA requests input on development of user fee program for biosimilar and interchangeable biological products
The U.S. Food and Drug Administration is requesting input from stakeholders and the public relating to the development of a user fee program for biosimilar and interchangeable biological product (351(k)) applications.